The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
 
John Ebben
No Relationships to Disclose
 
Jens C. Eickhoff
Consulting or Advisory Role - Abbvie; AIQ Solutions; AIQ Solutions; Dhristi; Five Prime Therapeutics; GlaxoSmithKline; Syneos Health
Research Funding - Sanofi Pasteur (Inst)
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Foundation Medicine; Illumina; Lilly; Pfizer; Regeneron; Seagen; STRATA Oncology
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Merck; Processa Pharmaceuticals
Other Relationship - seage
 
Anita Ahmed Turk
Consulting or Advisory Role - KLM Solutions
Research Funding - Lilly (Inst); Merck (Inst)
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; Delcath Systems; Histosonics; Incyte; Ipsen; Rafael Pharmaceuticals; SERVIER; Taiho Oncology
Research Funding - Actuate Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Esanik (Inst); Exelixis (Inst); FibroGen (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); SERVIER (Inst); Syros Pharmaceuticals (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
Other Relationship - Rafael Pharmaceuticals (Inst)
 
Nataliya Volodymyrivna Uboha
Stock and Other Ownership Interests - Exact Sciences (I); Natera (I)
Consulting or Advisory Role - Aptitude Health; Arcus Biosciences; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; BostonGene; Bristol Myers Squibb Foundation; Bristol-Myers Squibb/Roche; Eisai/MSD; Elevation Oncology; GRAIL; Helsinn Therapeutics; Ipsen; ipsen; Lilly; Pfizer; Strata Oncology
Research Funding - Arcus Biosciences (Inst); EMD Serono (Inst); ipsen (Inst)